Lv41
500 积分 2022-03-30 加入
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
1小时前
求助中
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
1小时前
已完结
Cancer-fighting immune cells could soon be engineered inside our bodies
4个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
1年前
已完结
Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy
1年前
已完结
How I treat post-immunotherapy relapsed B-ALL
1年前
已完结
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
1年前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
1年前
已关闭
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
1年前
已完结
CAR T Cells — A New Horizon for Autoimmunity?
1年前
已完结
皖公网安备34019202002308
